
Genmab's collaborative partner Janssen has received a European marketing Authorization for Darzalex for treating the rare disease Light-chain (AL) amyloidosis.
The EU Commission has reached this decision on Tuesday after an expert panel recommended approving Darzalex in May.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app